Berdel AF, Röllig C, Burkhard-Meier C, Tembrink M, Unglaub JM, Sauer T, Crysandt M, Jost E, Jaeger P, Kiefel C, Fransecky L, Braitsch K, Götze K, Wille K, Schäfer-Eckart K, Metzeler K, Hilber S, Ronnacker J, Kemper M, Hölscher N, Wethmar K, Schroeder T, Herold S, Poitz D, Steffen B, Rank A, Hänel M, Middeke JM, Kaufmann M, Burchert A, Schetelig J, Platzbecker U, Thiede C, Stelljes M, Lenz G, Serve H, Baldus C, Bornhäuser M, Müller-Tidow C, Mikesch J-H, Frenzel L, Hanoun M, Ruhnke L, Schliemann C. Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification. haematol [Internet]. 2020Sep.10 [cited 2026Sep.13];. Available from: https://haematologica.org/article/view/14352